Scarica l'app Stockscreener
20.05
3.79%
-0.79
Dopo l'orario di chiusura:
20.45
0.40
+2.00%
Precedente Chiudi:
$20.84
Aprire:
$20.76
Volume 24 ore:
275.24K
Relative Volume:
3.08
Capitalizzazione di mercato:
$1.26B
Reddito:
-
Utile/perdita netta:
$-143.59M
Rapporto P/E:
-7.1009
EPS:
-2.8236
Flusso di cassa netto:
$-119.47M
1 W Prestazione:
-15.51%
1M Prestazione:
+16.57%
6M Prestazione:
+6.99%
1 anno Prestazione:
+12.26%
Intervallo 1D:
$20.05
$21.30
Intervallo di 1 settimana:
$20.05
$24.05
Portata 52W:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Confronta PHVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
20.05 | 1.26B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Guggenheim | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
How Pharvaris N.V. stock reacts to Fed policy changesRapidly growing investment returns - jammulinksnews.com
Pharvaris Raises $201 Million in Successful Offering - TipRanks
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Stock Titan
Is Pharvaris N.V. a good long term investmentRapid growth opportunities - Autocar Professional
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations (PHVS) - Seeking Alpha
What drives Pharvaris N.V. stock priceHigh-yield capital appreciation - jammulinksnews.com
Pharvaris shares slide following $175 million equity offering - MSN
Pharvaris stock drops after pricing $175 million public offering By Investing.com - Investing.com Nigeria
What analysts say about Pharvaris N.V. stockOutstanding growth strategies - Autocar Professional
Pharvaris' $175M Equity Raise: A Strategic Catalyst for HAE Market Leadership - AInvest
Pharvaris N.V. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
Pharvaris' $175M Equity Raise: Fueling a Strategic Leap in the HAE Market - AInvest
Pharvaris prices $175 million public offering to fund angioedema programs By Investing.com - Investing.com India
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
Pharvaris prices $175 million public offering to fund angioedema programs - Investing.com
Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline - Stock Titan
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire Inc.
Pharvaris' $150M Share Offering: Balancing Dilution Risk and HAE Market Capture in a High-Margin Niche - AInvest
IKNA issues special CVR dividend ahead of Inmagene merger | PHVS SEC FilingForm 424B5 - Stock Titan
Pharvaris announces $150M ordinary shares offering - TipRanks
Pharvaris Announces Proposed Public Offering of Ordinary Shares - The Manila Times
Pharvaris Seeks $150M in Public Offering: Major Push for Late-Stage HAE Drug Development - Stock Titan
Understanding Stock Volatility in the Indian Market AI Driven Stock AlertsFree Risk Assessment Services - Autocar Professional
Property Share Investment Trust (544295) Hits 52 Week HighRapid wealth creation - Autocar Professional
What drives PTON stock priceBreakout stock performance - jammulinksnews.com
What drives iShares Gold Trust stock priceHigh-yield capital appreciation - jammulinksnews.com
NSE Quality Stocks Smart Investor Club PicksHigh-velocity gains - jammulinksnews.com
Best Renewable Stocks Smart Money Stock PicksPowerful growth strategies - jammulinksnews.com
What risks could impact Pharvaris N.V. stock performanceHigh Return Stock Alerts - Newser
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success - Seeking Alpha
How To Trade (PHVS) - news.stocktradersdaily.com
Why Pharvaris N.V. stock attracts strong analyst attentionGrowth Optimized Stock Radar - beatles.ru
How Pharvaris N.V. stock performs during market volatilityFree Investment Community - Newser
What makes Pharvaris N.V. stock price move sharplyReal Time Alert Service - Newser
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):